GlaxoSmithKline has penned deals offering its pandemic vaccine adjuvant to several developers of COVID-19 shots. And it needs to amp up supply for those companies to make enough doses of their final products.
Now, the British pharma said it will make 1 billion doses of the adjuvant, dubbed AS03, in 2021 for use in multiple COVID-19 vaccine candidates.
Theoretically, the adjuvant can increase the body’s immune response to the vaccine component it’s paired with, reducing the amount of vaccine needed for each shot and allowing manufacturers to make more doses.
Comments are closed.